Drugs in development could result in better hepatitis C treatment

07/21/2010 | New York Times (tiered subscription model), The

About two dozen pharmaceutical firms are pursuing medicines for hepatitis C that could make treatment far more effective and less taxing. The drugs, including Vertex Pharmaceuticals' telaprevir and Merck & Co.'s boceprevir, could give hope to an estimated 300,000 hepatitis C patients who have not responded to existing treatment.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC